Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases

References

• Li Y-S, Jiang B-Y, Yang -J-J, Tu H-Y, Zhou Q, Guo W-B, Yan -H-H, Wu Y-L. Leptomeningeal metastases in patients with nsclc with egfr mutations. J Thorac Oncol. 2016;11:1962–1969. doi:10.1016/j.jtho.2016.06.029.
   PubMed Web of Science ®Google Scholar
• Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Heideman DAM, Berk Y, Buijs EJM, Speel E-JM, et al. Treatment and survival of patients with egfr-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. Lung Cancer. 2015;89:255–261. doi:10.1016/j.lungcan.2015.05.023.
   PubMed Web of Science ®Google Scholar
• Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012;7:382–385. doi:10.1097/JTO.0b013e3182398e4f.
   PubMed Web of Science ®Google Scholar
• Gwak H-S, Joo J, Kim S, Yoo H, Shin SH, Han J-Y, Kim HT, Lee JS, Lee SH. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non–small-cell lung cancer. J Thorac Oncol. 2013;8:599–605. doi:10.1097/JTO.0b013e318287c943.
   PubMed Web of Science ®Google Scholar
• Remon J, Le Rhun E, Besse B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. Cancer Treat Rev. 2017;53:128–137. doi:10.1016/j.ctrv.2016.12.006.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Cho BC, Kim D-W, Kim S-W, Lee J-S, Su W-C, John T, Kao SC-H, Natale R, Goldman JW, et al. Osimertinib for patients (pts) with leptomeningeal metastases (lm) from egfr-mutant non-small cell lung cancer (nsclc): updated results from the bloom study. J Clin Oncol. 2017;35:2020–2020.
   Google Scholar
• Ahn M-J, Kim D-W, Cho BC, Kim S-W, Lee J-S, Ahn JS, Kim TM, Lin -C-C, Kim H, John T, et al. Phase i study (bloom) of azd3759, a bbb penetrable egfr inhibitor, in patients with tki-naive, egfrm nsclc with cns metastases. J Clin Oncol. 2017;35:2006-2006. doi:10.1200/JCO.2017.35.15_suppl.2006.
   Google Scholar
• Lee E, Keam B, Kim D-W, Kim TM, Lee S-H, Chung DH, Heo DS. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non–small-cell lung cancer. J Thorac Oncol. 2013;8:1069–1074. doi:10.1097/JTO.0b013e318294c8e8.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Lee J-I, Nam D-H, Ahn YC, Han JH, Sun J-M, Ahn JS, Park K, Ahn M-J. Leptomeningeal carcinomatosis in non–small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol. 2013;8:185–191. doi:10.1097/JTO.0b013e3182773f21.
   PubMed Web of Science ®Google Scholar
• Wang Y, Springer S, Zhang M, McMahon KW, Kinde I, Dobbyn L, Ptak J, Brem H, Chaichana K, Gallia GL, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Nat Acad Sci. 2015;112:9704–9709. doi:10.1073/pnas.1511694112.
   Google Scholar
• De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839. doi:10.1038/ncomms9839.
   PubMed Web of Science ®Google Scholar
• Vanden Bempt I, Wauters E, Vansteenkiste J. Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in egfr-mutant nsclc. Ann Oncol. 2018;29:789–791. doi:10.1093/annonc/mdy053.
   Google Scholar
• Crowley E, Di NF, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472. doi:10.1038/nrclinonc.2013.110.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. doi:10.1126/scitranslmed.3007094.
   PubMed Web of Science ®Google Scholar
• Pan W, Gu W, Nagpal S, Gephart MH, Quake SR. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015;61:514–522. doi:10.1373/clinchem.2014.235457.
   PubMed Web of Science ®Google Scholar
• Li YS, Jiang BY, Yang JJ, Zhang XC, Zhang Z, Ye JY, Zhong WZ, Tu HY, Chen HJ, Wang Z, et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of egfr-mutant non-small cell lung cancer: A new medium of liquid biopsy. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:945–952. doi:10.1093/annonc/mdy009.
   PubMed Web of Science ®Google Scholar
• Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol. 2016; 34:2404–2415. doi:10.1200/JCO.2016.66.6487.
   PubMedGoogle Scholar
• Fan Y, Zhu X, Xu Y, Lu X, Xu Y, Wang M, Xu H, Ding J, Ye X, Fang L, et al. Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer. Clin Cancer Res. 2018;24:209–216. doi:10.1158/1078-0432.CCR-17-1582.
   PubMed Web of Science ®Google Scholar
• Li H, Durbin R. Fast and accurate long-read alignment with burrows–wheeler transform. Bioinf. 2010;26:589–595. doi:10.1093/bioinformatics/btp698.
   PubMed Web of Science ®Google Scholar
• Yang H, Cai L, Zhang Y, Tan H, Deng Q, Zhao M, Xu X. Sensitive detection of egfr mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases. J Mol Diagn JMD. 2014;16:558–563. doi:10.1016/j.jmoldx.2014.04.008.
   PubMed Web of Science ®Google Scholar
• Nanjo S, Arai S, Wang W, Takeuchi S, Yamada T, Hata A, Katakami N, Okada Y, Yano S. Met copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of egfr-mutant lung cancer. Mol Cancer Ther. 2017;16:506–515. doi:10.1158/1535-7163.MCT-16-0522.
   PubMed Web of Science ®Google Scholar
• Hata A, Katakami N, Yoshioka H, Kaji R, Masago K, Fujita S, Imai Y, Nishiyama A, Ishida T, Nishimura Y, et al. Spatiotemporal t790m heterogeneity in individual patients with egfr-mutant non-small-cell lung cancer after acquired resistance to egfr-tki. J Thoracic Oncol: off Publ Int Assoc Study Lung Cancer. 2015;10:1553–1559. doi:10.1097/JTO.0000000000000647.
   Google Scholar
• Geukes Foppen M, Brandsma D, Blank C, van Thienen J, Haanen J, Boogerd W. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Ann Oncology Official Journal Eur Soc Med Oncol. 2016;27:1138–1142. doi:10.1093/annonc/mdw134.
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;4:S265. doi:10.4103/2152-7806.111304.
   PubMedGoogle Scholar
• Scott BJ, Kesari S. Leptomeningeal metastases in breast cancer. Am J Cancer Res. 2013;3:117.
   PubMed Web of Science ®Google Scholar
• Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, et al. Efficacy of the irreversible erbb family blocker afatinib in epidermal growth factor receptor (egfr) tyrosine kinase inhibitor (tki)–pretreated non–small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10:156–163. doi:10.1097/JTO.0000000000000380.
   PubMed Web of Science ®Google Scholar
• Pan W, Gu W, Nagpal S, Gephart MH, Quake SR. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015;61:514–522. doi:10.1373/clinchem.2014.235457.
   PubMed Web of Science ®Google Scholar
• Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016. doi: 10.1158/2159-8290.CD-15-1483.
   PubMed Web of Science ®Google Scholar
• Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. Egfr mutation status on brain metastases from non-small cell lung cancer. Lung Cancer. 2016;96:101–107. doi:10.1016/j.lungcan.2016.04.004.
   PubMed Web of Science ®Google Scholar
• Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, et al. Brain metastases in patients with egfr-mutated or alk-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88:108–111. doi:10.1016/j.lungcan.2015.01.020.
   PubMed Web of Science ®Google Scholar
• Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, Shukuya T, Kido K, Iwakami S, Tominaga S, Takahashi K. Diagnostic significance of cerebrospinal fluid egfr mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active egfr mutation following gefitinib therapy failure. Respir Investig. 2016;54:14–19. doi:10.1016/j.resinv.2015.07.001.
   PubMed Web of Science ®Google Scholar
• Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, et al. Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: comparison between t790m mutation‐positive and mutation‐negative populations. Cancer. 2013; 119:4325–4332. doi:10.1002/cncr.28364.
   PubMed Web of Science ®Google Scholar
• Zhao J, Ye X, Xu Y, Chen M, Zhong W, Sun Y, Yang Z, Zhu G, Gu Y, Wang M. Egfr mutation status of paired cerebrospinal fluid and plasma samples in egfr mutant non-small cell lung cancer with leptomeningeal metastases. Cancer Chemother Pharmacol. 2016;78:1305–1310. doi:10.1007/s00280-016-3155-y.
   PubMed Web of Science ®Google Scholar
• Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to egfr inhibitors and the development of brain metastasis. Am J Pathol. 2010;177:415–423. doi:10.2353/ajpath.2010.090863.
   PubMed Web of Science ®Google Scholar
• Ni X, Zhuo M, Su Z, Duan J, Gao Y, Wang Z, Zong C, Bai H, Chapman AR, Zhao J, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proceedings of the National Academy of Sciences 2013;110:21083–21088. doi:10.1073/pnas.1320659110.
   Google Scholar
• Le Ba, Vitte A-L, Debernardi A, Curtet S, Buchou T, Vayr J, Reyniès A, Ito A, Guardiola P, Brambilla C, et al. Receptor-independent ectopic activity of prolactin predicts aggressive lung tumors and indicates hdaci-based therapeutic strategies. Antioxid Redox Signal. 2015;23:1–14. doi:10.1089/ars.2013.5581.
   PubMed Web of Science ®Google Scholar
• Muralidhar K, Lee J. Prolactin and angiogenesis: biological implications of microheterogeneity. In: Prolactin. InTech. 2013. doi:10.5772/54318.
   Google Scholar
• Aksamitiene E, Achanta S, Kolch W, Kholodenko BN, Hoek JB, Kiyatkin A. Prolactin-stimulated activation of erk1/2 mitogen-activated protein kinases is controlled by pi3-kinase/rac/pak signaling pathway in breast cancer cells. Cell Signal. 2011;23:1794–1805. doi:10.1016/j.cellsig.2011.06.014.
   PubMed Web of Science ®Google Scholar
• Yan A, Chen Y, Chen S, Li S, Zhang Y, Jia J, Yu H, Liu L, Liu F, Hu C, et al. Leptin stimulates prolactin mrna expression in the goldfish pituitary through a combination of the pi3k/akt/mtor, mkk3/6/p38mapk and mek1/2/erk1/2 signalling pathways. Int J Mol Sci. 2017;18:2781. doi:10.3390/ijms18122781.
   Web of Science ®Google Scholar
• Hartwell HJ, Petrosky KY, Fox JG, Horseman ND, Rogers AB. Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-myc in mice. Proc Natl Acad Sci U S A. 2014;111:11455–11460. doi:10.1073/pnas.1404267111.
   PubMed Web of Science ®Google Scholar